CAN-3110
Recurrent High-Grade Glioma
Key Facts
About Candel Therapeutics
Candel Therapeutics is a clinical-stage biotech focused on developing multimodal oncolytic viral immunotherapies for cancer. Its mission is to leverage engineered adenovirus and herpes simplex virus (HSV) platforms to induce immunogenic cell death and train the immune system to fight tumors. The company's strategy centers on advancing its lead candidates, CAN-2409 and CAN-3110, through late-stage trials in non-small cell lung cancer (NSCLC), prostate cancer, pancreatic cancer, and brain cancer, aiming to generate pivotal data for regulatory submissions. As a publicly traded, pre-revenue entity, Candel's near-term value is tied to clinical milestones and partnership potential in the competitive immuno-oncology landscape.
View full company profileTherapeutic Areas
Other Recurrent High-Grade Glioma Drugs
| Drug | Company | Phase |
|---|---|---|
| DB107 (Toca 511 & Toca FC) | Denovo Biopharma | Phase 2/3 |
| NanO₂ | NuvOx Therapeutics | Phase II |
| SRN-101 | Siren Biotechnology | Phase 1 |
| DSP-0390 | Sumitomo Pharma | Phase 1/2 |